# Kaleido

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kaleido

- Industry: Medical Devices & Equipment
- Headquarters: Utrecht, Netherlands
- Website: www.hellokaleido.com
- Total disclosed funding: $182M
- Latest round: Series D (Jan 8, 2026)
- Investors on record: 9

## About

Founded in 2013 and based in Utrecht, Netherlands, the current CEO is Frans Cromme, and the founder, Tim Oakes, ViCentra B.V., trading under the name Kaleido an insulin delivery solution aimed at individuals with diabetes. The Kaleido Insulin Pump features customizability with various colors and integrates with the DBLG1 algorithm and Dexcom G6 monitoring system for real-time adjustments. In January 2026, Kaleido raised USD 13 million in series D funding from new investors ROM Utrecht Region, Venturing Tech, with participation from returning investor Innovation Industries. Other unspecified investors also participated in the round.

ViCentra B.V. developed Kaleido, an insulin delivery solution aimed at individuals with diabetes. The Kaleido Insulin Pump features customizability with various colors and integrates with the DBLG1 algorithm and Dexcom G6 monitoring system for real-time adjustments. Currently, these products are primarily available in Germany and the Netherlands, catering to adults with diabetes and their healthcare providers while prioritizing ease of use and sustainability.
In 2023, ViCentra B.V. reported a revenue of EUR 1,503,364 with an EBITDA of EUR -10,266,035, generated mainly from the sales of its insulin pumps and consumables, including a Starter Kit offering two pumps with a four-year warranty.

The company will use the January 2026 funding to support the further enhancement of its manufacturing capabilities and expansion plans initiatives.

## Funding rounds

- Series D, Jan 8, 2026, $13M — Innovation Industries, ROM Utrecht Region, Venturing Tech
- Series D, Sep 3, 2025, $85M — EQT Life Sciences, Health Innovations, Innovation Industries, Invest-NL, Partners in Equity
- Series C, Dec 16, 2021, $73M — EQT Life Sciences, Inkef, Health Innovations, Partners in Equity
- Series B, Jun 1, 2015, $11M — EQT Life Sciences, Inkef, Health Innovations
- Seed, Mar 12, 2013 — Merck Global Health Innovation Fund, Inkef

## Investors

- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Seed
- Inkef (https://capitalatlas.ai/funds/inkef) — Seed, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C, Series D
- Health Innovations (https://capitalatlas.ai/funds/health-innovations) — Series B, Series C, Series D
- Partners in Equity (https://capitalatlas.ai/funds/partners-in-equity) — Series C, Series D
- Innovation Industries (https://capitalatlas.ai/funds/innovation-industries) — Series D
- Invest-NL — Series D
- ROM Utrecht Region (https://capitalatlas.ai/funds/rom-utrecht-region) — Series D
- Venturing Tech (https://capitalatlas.ai/funds/venturing-tech) — Series D